LobbyingNational Breast Cancer Coalition Fund lobbying by quarter
National Breast Cancer Coalition Fund's latest lobbying report covers Q2 2026, at $71.3K. The four quarters Q4 2025–Q3 2026 total $228.2K. Its first report covers Q4 2022; the issues it reports most are Defense and Budget/Appropriations.
National Breast Cancer Coalition Fund
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $228.2K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $69.5K | 2 |
| Q1 2023 | $78.4K | 2 |
| Q2 2023 | $88.6K | 2 |
| Q3 2023 | $77.2K | 2 |
| Q4 2023 | $85.3K | 2 |
| Q1 2024 | $74.9K | 2 |
| Q2 2024 | $92.8K | 2 |
| Q3 2024 | $77.6K | 2 |
| Q4 2024 | $80.1K | 2 |
| Q1 2025 | $83.1K | 2 |
| Q2 2025 | $91.8K | 2 |
| Q3 2025 | $87.4K | 2 |
| Q4 2025 | $86.8K | 2 |
| Q1 2026 | $70.1K | 2 |
| Q2 2026 | $71.3K | 2 |
| Q3 2026 | $0 | 0 |
By issue
- Defense$1.1M · 19 reports
- Budget and appropriations$45K · 9 reports
- Medicare and Medicaid$45K · 9 reports
- Health issues$30K · 5 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- SENATE28 reports
- HOUSE OF REPRESENTATIVES14 reports
- White House Office3 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseNational Breast Cancer Coalition Fund | $1.1M | 15 quarters |
| NVG | $140K | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | NVG | $10K |
| 07/20for Q2 | In-house | $61.3K |
| 04/20for Q1 | NVG | $10K |
| 04/17for Q1 | In-house | $60.1K |
| 01/20for Q4 2025 | NVG | $10K |
| 01/20for Q4 2025 | In-house | $76.8K |
| 25/10/20for Q3 2025 | NVG | $10K |
| 25/10/20for Q3 2025 | In-house | $77.4K |
| 25/07/20for Q2 2025 | NVG | $10K |
| 25/07/14for Q2 2025 | In-house | $81.8K |
| 25/04/19for Q1 2025 | NVG | $10K |
| 25/04/18for Q1 2025 | In-house | $73.1K |
| 25/01/20for Q4 2024 | NVG | $10K |
| 25/01/17for Q4 2024 | In-house | $70.1K |
| 24/10/21for Q3 2024 | In-house | $67.6K |
| 24/10/21for Q3 2024 | NVG | $10K |
| 24/07/22for Q2 2024 | In-house | $82.8K |
| 24/07/22for Q2 2024 | NVG | $10K |
| 24/04/22for Q1 2024 | NVG | Under $5,000 |
| 24/04/19for Q1 2024 | In-house | $74.9K |